Impact Biomedical (IBO) Long-Term Investments (2022 - 2023)
Impact Biomedical's (IBO) quarterly Long-Term Investments came in at $782000.0 in Q2 2023, little changed on a QoQ basis from $782000.0 in Q4 2022.
Impact Biomedical (IBO) Long-Term Investments (2022 - 2023) Analysis & Trends
Impact Biomedical (IBO) has 2 years of Long-Term Investments data on file, last reported at $782000.0 in Q2 2023.
- Quarterly Long-Term Investments changed N/A year-over-year to $782000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $782000.0 (changed N/A YoY) and the FY2022 annual result came in at $782000.0, changed N/A from the prior year.
- Long-Term Investments was little changed at $782000.0 in Q2 2023, from $782000.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $782000.0 in Q4 2022 to a low of $782000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 782,000.00 |
| Dec 31, 2022 | 782,000.00 |